QTNT - Quotient teams up with InfYnity Biomarkers to advance infectious disease testing
- Quotient ( NASDAQ: QTNT ) is collaborating with R&D firm InfYnity Biomarkers to advance infectious disease testing by using Quotient’s MosaiQ solution.
- Under the agreement, InfYnity will help Quotient in the research and design of infectious disease assays to expand the MosaiQ Serology Disease Screening menu and reduce time and cost of developing and commercializing.
- Quotient ( QTNT ) said in a July 12 press release that InfYnity is developing antibodies and antigens for multiplexed infectious disease blood screening, confirmatory testing, determining vaccine efficacy, and monitoring testing which will be evaluated as part of the collaboration.
- QTNT +4.97% to $0.29 premarket July 12
For further details see:
Quotient teams up with InfYnity Biomarkers to advance infectious disease testing